This book concisely covers the latest developments in the application of direct oral anticoagulants (DOACs) within cardiovascular medicine. It details the pharmacodynamics and pharmacokinetic mechanisms of DOACs and their application in treating patients with conditions ranging from coronary heart disease through kidney disease and cancer, including their perioperative management. Direct Oral Anticoagulants: From Pharmacology to Clinical Practice systematically describes the underlying mechanisms associated with DOACs and their use to treat a range of conditions and is an indispensable resource for all trainee and practicing physicians in a range of disciplines seeking a concise up-to-date resource on the topic.

Anticoagulant drugs are among the most frequently prescribed drugs in everyday clinical practice. In the past decades, several new direct oral anticoagulants were developed that changed the anticoagulant therapy landscape considerably. This book provides an extensive overview of all the known anticoagulants that can be useful for studying different aspects of the haemostatic system or as a starting point for new drug development. It is also a valuable tool for clinicians providing a description of the mode of action and management of therapy for anticoagulant drugs used in everyday clinical practice in different clinical settings, including direct oral anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban.

This book presents the latest evidence and guidelines supporting the use of anticoagulant therapy for various clinical scenarios. The field of anticoagulation therapy is evolving rapidly, particularly since the arrival and widespread adoption of direct oral anticoagulants. Organized in two parts, this book reviews the pharmacologic properties of various anticoagulants and details the clinical applications of anticoagulant therapy. Drugs such as warfarin and unfractionated heparin, as well as parenteral and direct oral anticoagulants are discussed in terms of their pharmacokinetics, drug-disease interactions, dosing strategies, and risk considerations. Clinical applications of anticoagulant therapy in disorders such as acute coronary syndromes, atrial fibrillation, and thrombophilia and in special populations such as pregnant women, the elderly, and in the patient with cancer are highlighted. Clinical vignettes, algorithms, clinical pearls, and self-assessment questions are integrated throughout the book. Featuring contributions from authorities in the field, Anticoagulation Therapy is an essential resource for cardiologists, vascular medicine specialists, hematologists, internists, and all other healthcare professionals who prescribe anticoagulants.

Showcasing the expertise of top-tier specialists who contributed to the newly released guidelines for the care of thrombosis in cancer patients, this exciting guide was written and edited by members of the American Society of Clinical Oncology panel, (ASCO), on the prevention and treatment of cancer-associated thrombosis, among others, and provides

Get a quick, expert overview of stroke risks among patients with treated and untreated atrial fibrillation, in addition to best practices for management and treatment of patients with atrial fibrillation to minimize stroke risks. This concise, clinically-focused resource by Dr. Greg Flaker consolidates today's available information on this timely topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee cardiologists as well as general practitioners treating and monitoring these patients. - Covers a broad spectrum of management and treatment options for atrial fibrillation including anticoagulants, surgical and implanted devices. - Presents information on recent drug trials to keep you up to date with the latest developments. - Includes guidance on anticoagulation in special situations, such as cardioversion and ablation, in addition to atrial fibrillation treatment in patients with other medical conditions including cancer, major bleeding disorders, and renal or liver disease. - Chapter on Risk Stratification assists in identifying patients with a high risk of stroke and predicting treatment outcomes. - Chapter on The New Anticoagulation Clinic overviews best practices for patient education, compliance, follow-up monitoring, and quality assurance to aid in better patient outcomes.

Clinical application of antithrombotic therapy in both arterial disease (acute coronary syndromes, acute MI, peripheral arterial disease, valvular heart disease, atrial fibrillation) and venous disease, (venous thromboembolic disease and pulmonary embolism). Results of major clinical trials and their implications for clinical practice.

Venous thromboembolism (VTE) occurs less often in children than adults and therefore remains underrecognized despite increasing in incidence. Due to the risk of mortality, short- and long-term morbidity, and increased healthcare costs associated with pediatric VTE, this entity merits better understanding and consideration. With this Research Topic, we aim to highlight some special considerations of pediatric VTE, namely risk factors and epidemiology, rare types of pediatric thrombosis and considerations unique to specific clinical patient subgroups, approaches to management and treatment, and prevention.

This book describes the pathways of dissemination of primary liver, biliary, and pancreatic neoplasms and proposes a practical and clinically driven approach to their imaging. The typical dissemination pathways for hepatocellular carcinoma, cholangiocarcinoma, exocrine pancreatic carcinoma, and neuroendocrine pancreatic tumors are systematically reviewed, and more unusual pathways are also documented. The content is presented in an extremely schematic way, with numerous high-quality graphical illustrations and multimodality images (US, CT, MRI, and PET) that are accompanied by clear explanatory text. The clinical significance of findings and potential therapeutic options are explained whenever appropriate. In addition, relevant background information is provided on the role of morphopathological drivers of cancer spread and anatomy.

Although highly effective in preventing thromboembolic events, the safe management of anticoagulant therapy continues to be a major challenge, requiring constant monitoring and coordinated models of patient-centered care. Anticoagulation Therapy: A Clinical Practice Guide, Second Edition, helps take the guesswork out of managing these therapies and provides essential recommendations. This revised and expanded edition includes: Extensive new information on the direct oral anticoagulants (DOACs) Expanded information on anticoagulant reversal and expanded use of prothrombin complex concentrates New chapters on the use of anticoagulants in special patient populations, the use of anticoagulants in patients with mechanical devices, anticoagulation care delivery standards, regulatory issues, and more Four new appendices on the effect of DOACs on chemotherapy, nutritional influences, types of central nervous system hemorrhage, and use of anticoagulation in patients with coagulopathies

The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists.